Lilly is making three acquisitions at once on Tuesday, for up to $3.8 billion total, to increase its presence in infectious disease. The pharma is buying Curevo, LimmaTech Biologics and Vaccine Company.

Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.

The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss drugs